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Background: Induction chemotherapy has been investigated as a possible strategy to shrink or downstage locally
advanced head and neck cancers, providing opportunity to remove the lesions completely after induction
chemotherapy, especially in the patients with resectable advanced disease. The aim of this study was to investigate
the definitive effect of induction chemotherapy in patients with resectable head and neck squamous cell
carcinoma.
Methods: A meta-analysis of randomized trials (1965–2011) was performed on the impact of induction
chemotherapy on survival, disease control, and toxicity in this population of patients. Kaplan-Meier curves were
read by Engauge-Digitizer. Data combining was performed using RevMan.
Results: Fourteen trials (2099 patients) were involved in this analysis. There was no significant difference on overall
survival, disease free survival, or locoregional recurrence between the patients treated with and without induction
chemotherapy (P >0.05). However, the patients treated with induction chemotherapy had a lower rate of distant
metastasis by 8% (95% confidence interval 1%–16%, P = 0.02) than those treated without induction chemotherapy.
In patients with laryngeal cancer, comparing to radical surgery, the larynx could be preserved in responders to
induction chemotherapy without survival decease (P >0.05). Induction chemotherapy-associated death was 0%–5%.
Conclusions: Based on the results above, there is a significant benefit of induction chemotherapy on decreasing
distant metastasis in patients with resectable head and neck squamous cell carcinoma. In patients with laryngeal
cancer, induction chemotherapy provides larynx preservation in responders to induction chemotherapy.
Keywords: Induction chemotherapy, Resectable head and neck squamous cell carcinoma, Randomized controlled
trial, Meta-analysisBackground
Head and neck squamous cell carcinoma (HNSCC) ranks
sixth among the most common cancers worldwide with
an incidence of over 500,000 new cases each year [1]. Pa-
tients at an early stage clinical (stages I and II), are typic-
ally treated with single modality therapy, usually surgery
or radiation therapy, with excellent disease control and
long-term survival. For patients with more advanced dis-
ease, at clinical stages III and IV, comprehensive, sequen-
tial treatment regimens consisting of surgery, and/or* Correspondence: zhonglp@hotmail.com
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reproduction in any medium, provided the orradiotherapy, with or without chemotherapy are mostly
required [2]. However, the prognosis has not been signifi-
cantly improved; the 5-year survival rate remains about
50% to 60%, and is even lower in the patients at late clin-
ical stages [3].
Induction chemotherapy has been investigated as a pos-
sible strategy to shrink or downstage locally advanced
head and neck cancers, increase organ preservation rates,
and/or reduce the risk of locoregional and/or distant re-
currence, ultimately improving treatment outcomes. How-
ever, it should be noted that after induction chemotherapy
locoregional treatment should be performed according to
the original tumor borders, which should be marked with
a tattoo or ink before treatment initiation; for example,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Ma et al. World Journal of Surgical Oncology 2013, 11:67 Page 2 of 7
http://www.wjso.com/content/11/1/67after preoperative induction chemotherapy, in order to re-
move the tumor completely, surgical resection should be
performed according to the original tumor borders,
regardless of the response to induction chemotherapy.
Drug delivery is postulated to be better in untreated well-
vascularized tumors before surgery and/or radiotherapy
than that after surgery and/or radiotherapy. However,
there is still debate about the clinical value of induction
chemotherapy, especially for resectable HNSCC. Both
positive and negative results from randomized controlled
trials (RCTs) have been reported, and previous systematic
reviews of these results have not merited a clear-cut bene-
fit of induction chemotherapy on overall survival [4-7].
For locally advanced and resectable HNSCC, there is still
no systemic analysis of the outcomes of induction chemo-
therapy followed by locoregional treatment compared to
locoregional treatment alone, thus, we performed a meta-




RCTs were eligible if they were studies of previously un-
treated patients with resectable non-metastatic HNSCC,
comparing induction chemotherapy followed by locore-
gional treatment (comprising surgery, or radiotherapy
or chemoradiotherapy, or surgery plus radiotherapy or
chemoradiotherapy) versus locoregional treatment. The
RCTs for larynx preservation were also eligible if they had
compared radical surgery and radiotherapy versus induc-
tion chemotherapy, followed by radiotherapy or chemo-
radiotherapy in responders, or radical surgery and
radiotherapy or chemoradiotherapy in non-responders.
The RCTs were limited to those officially published in
English, and based on patients recruited between 1
January 1965 and 31 December 2011. Tumor sites in-
cluded the oral cavity, oropharynx, hypopharynx, and lar-
ynx with the exception of the nasopharynx.
Search strategy
Literature searching was conducted using the database of
MEDLINE from 1965 to 2011 and EMBASE from 1980
to 2011. Reference lists and conference proceedings were
also searched to identify possible additional RCTs.
The following search codes were used: induction chemo-
therapy.tw, induc$ chemotherapy.tw, neoadjuvant chemo-
therapy.tw, preoperative chemotherapy.tw, sequential
chemotherapy.tw, adjuvant chemotherapy.tw, primary
chemotherapy.tw, initial chemotherapy.tw, resectable.tw,
operable.tw, head and neck.tw, oral.tw, pharyngeal.tw,
oropharyngeal.tw, hypopharyngeal.tw, maxillofacial.tw, la-
ryngeal.tw, paranasal sinus.tw, randomized controlled tri-
als/, randomised-controlled-trial.pt, controlled-clinical
-trial.pt, random allocation/, exp clinical trials/, clinical-trial.pt, random$.ti,ab, comparative study/, follow-up
studies/, prospective studies/.
Data collection and analysis
Suitability of studies for inclusion was independently
assessed by two authors and any disagreement or lack of
clarity was resolved through discussion. We developed a
data extraction sheet based on the Cochrane Consumers
and Communication Review Group data extraction tem-
plate. The data, including patient number, age, sex,
tumor site, tumor, node, metastasis (TNM) stage, were
also extracted and checked by the two authors and dis-
agreement was resolved through discussion. If agree-
ment could not be reached between the two authors, a
third author would participate in the discussion and so
on, until reaching final agreement. The primary end-
point was overall survival. The secondary endpoints
were disease-free survival, locoregional recurrence, and
distant metastasis.
The time-to-event data from individual trials were sum-
marized by the log hazard ratio (HR) and its variance. If
the trials did not report this information directly, appro-
priate data, such as the P-value from the log-rank test
were extracted to estimate the log HR and its variance
[8], and the time-to-event data were extracted from the
survival curves. Kaplan-Meier curves were read by the
Engauge Digitizer version 4.1 (free software downloaded
from http://sourceforge.net). Data combining was per-
formed by RevMan version 5.1 (free software downloaded
from http://www.cochrane.org). The log HR and its vari-
ance were pooled using an inverse variance weighted
average, and the results were presented as an HR and
95% CI.
DerSimonian-Laird random effect analysis was used to
estimate the survival difference [9]. This method gener-
ates a combined survival difference and a 95% CI with a
heterogeneity test at each endpoint. Survival rate was
derived from published survival curves if it was not pro-
vided explicitly in the text or tables. Subjects censored
prior to each endpoint were subtracted from the denom-
inators (number of patients during follow-up), giving a
conservative CI for the summary statistic. Censored
cases were counted by placing tick marks on survival
curves when provided [10].
Heterogeneity was assessed by inspection of the forest
plot, the Cochran chi-squared (χ2) test, and the I2 statis-
tic percentage. A fixed effect approach was adopted un-
less there was significant evidence of unexplained
heterogeneity, in which case a random effects approach
was used.
Results
A total of 9,612 citations were identified from the data-
base of MEDLINE and EMBASE, and there were 18
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all of the authors, 14 RCTs (2,107 patients) [11-27] were
found to be eligible with complete and validated data for
meta-analysis (Figure 1).
Among the 14 RCTs, comparison between the patients
receiving induction chemotherapy followed by locore-
gional treatment (surgery and/or radiotherapy or chemo-
radiotherapy), and locoregional treatment alone (surgery
and/or radiotherapy or chemoradiotherapy) was reported
in 11 RCTs (1,505 patients) [11-23]. Comparison between
induction chemotherapy followed by surgery in non-re-
sponders or radiotherapy/chemoradiotherapy in respon-
ders, and radical surgery and radiotherapy was reported
in three RCTs, focusing on larynx preservation (602 pa-
tients) [24-27]. Although there were a few variations in
these trials, such as period of study and duration of fol-
low-up, the influence of study heterogeneity on theFigure 1 Study flow diagram.relative risk of disease-specific death was not significant
(I2 = 0%, P = 0.54). According to the toxicity of induction
chemotherapy as reported in the trials, the most common
toxicity effect was vomiting (8.5% to 24.5%), followed by
leukopenia (5.1% to 7.6%), mucositis (0.2% to 8.2%),
and thrombocytopenia (1.7% to 7.7%); the induction
chemotherapy-associated death rate was reported to be 0%
to 5%.
There was no significant difference in overall survival
between patients treated with and without induction
chemotherapy (HR = 1.01, 95% CI 0.88, 1.16, P = 0.84),
neither was there a significant difference according to the
protocol of induction chemotherapy, such as cisplatin and
5-fluorouracil (PF), other platin-containing combinations,
or multiple agents without platin (Figure 2). For disease-
free survival, there was no significant difference between
the patients treated with or without induction chemother-
apy (HR = 0.97, 95% CI 0.82, 1.15, P = 0.76) (Figure 3).
In the three RCTs of laryngeal or hypopharyngeal can-
cer (602 patients) focusing on larynx preservation [24-27],
compared to radical surgery followed by radiotherapy,
the larynx could be preserved after induction chemother-
apy in responders without decrease of overall survival
(HR = 1.21, 95% CI 0.72, 2.03, P = 0.47) or disease-free
survival (HR = 1.02, 95% CI 0.79, 1.31, P = 0.87).
There was no significant difference in long-term (5-year)
locoregional recurrence rate between patients treated with
or without induction chemotherapy (432 patients, ratio dif-
ference = 2%, 95% CI −12%, 16%, P = 0.76). However,
among patients who developed distant metastases (700 pa-
tients), those treated with induction chemotherapy had a
significantly lower long-term (5-year) rate of distant metas-
tases (8% difference, 95% CI 1%, 16%, P = 0.02), compared
to those treated without induction chemotherapy
(Figure 4).
Discussion
In this study, for patients with locally advanced and re-
sectable HNSCC, induction chemotherapy benefited these
patients in terms of an 8% lower rate for the occurrence
of distant metastases; however, induction chemotherapy
did not improve overall survival, disease-free survival or
locoregional control. The toxicity of induction chemo-
therapy was acceptable for further surgery, or radiother-
apy or chemoradiotherapy.
Previous meta-analyses of both resectable and unre-
sectable HNSCC [4-7] and this meta-analysis of resect-
able HNSCC confirm the effective decrease in the
development of distant metastases in the patients with-
out metastases at baseline (M0) treated with induction
chemotherapy and locoregional treatment, compared to
locoregional treatment alone. This is reasonable due to
the effect of induction chemotherapy on peripheral, po-
tentially metastatic tumor cells.
Figure 2 Forest plot of hazard ratios for overall survival and 95% CI in fourteen randomized controlled trials in patients with
resectable head and neck squamous cell carcinoma treated with induction chemotherapy followed by locoregional treatment, or
locoregional treatment alone. Richard 1991a23 is for cancer of the floor of the mouth, Richard 1991b23 is for cancer of the posterior oral cavity
and oropharynx. Volling 199413, Richard 199827, Lewin 199714, Paccagnella 200411, Domenge 200015, Licitra 200316, Lefebvre 199624, Veterans
Affairs 199827, Kohno 200021, Maipang 199519, Schuller 198820, Jortay 199022.
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no significant benefit of induction chemotherapy in the
patients with resectable HNSCC, even using the PF
protocol, which has been reported to be beneficial to
overall survival in other meta-analyses [4,6,7]. According
to the site of primary lesions, most of patients receivingFigure 3 Forest plot of hazard ratios for disease-free survival and 95%
carcinoma treated with induction chemotherapy followed by locoreg
is for cancer of the floor of the mouth, Richard 1991b23 is for cancer of the
Paccagnella 200411, Richard 199825, Veterans Affairs 199827, Volling 199413.PF induction chemotherapy in the present study were
oral cancer patients; while the previous studies of induc-
tion chemotherapy in HNSCC patients included not
only oral cancer, but also patients with oropharyngeal
and hypopharyngeal cancer. As we know, for oral cancer
patients with resectable lesions, radical surgery isCI in patients with resectable head and neck squamous cell
ional treatment, or locoregional treatment alone. Richard 1991a23
posterior oral cavity and oropharynx. Jacobs 198717, Lefebvre 199624,
Figure 4 Forest plot of hazard ratios of distant metastasis-free survival and 95% CI in patients with resectable head and neck
squamous cell carcinoma treated with induction chemotherapy followed by locoregional treatment, or locoregional treatment alone.
Richard 1991a23 is for cancer of the floor of the mouth, Richard 1991b23 is for cancer of the posterior oral cavity and oropharynx. Hasegawa
199618, Licitra 200316, Paccagnella 200411.
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operative radiotherapy or chemoradiotherapy, depending
on the presence of intermediate/high risk features in the
surgical specimen; and for patients with resectable locally
advanced oropharyngeal and hypopharyngeal cancer, sur-
gery, or radiotherapy or chemoradiotherapy, followed by
radiotherapy or chemoradiotherapy is considered the
standard of care. The efficiency of adding PF agents to
standard care may differ between patients with oral cancer,
and those with oropharyngeal or hypopharyngeal cancer.
So, the effect of PF induction chemotherapy may differ in
the patients with different primary tumor sites, and there-
fore, the primary tumor site might be considered before
adding PF induction chemotherapy. It appears that induc-
tion chemotherapy could be more effective in oropharyn-
geal and hypopharyngeal cancer than in oral cancer.
This could be due to various factors, such as high-risk hu-
man papilloma virus (HPV) infection, producing virus
oncoproteins of E6 and E7, which are necessary for viral
replication through their proliferation-stimulating activity,
and play a key role in malignant transformation and main-
tenance; they are also sensitive to cytotoxic chemotherapy
and DNA damage-induced apoptosis. Also, as we know,
the incidence of HPV in patients with oropharyngeal can-
cer is higher than in patients with oral cancer. Based on
the results of the present study, some factors might be
considered to improve the prognosis in future clinical tri-
als, such as insistence on radical surgery, even in patients
with clinical response, in order to reduce locoregional
failure and to improve survival, or optimization of the
induction chemotherapy protocol by adding new or
targeted drugs.
Recently, in two randomized phase III trials [3,28,29],
a new induction chemotherapy protocol of a combin-
ation of docetaxel, cisplatin and 5-fluorouracil (TPF)
followed by radiotherapy or chemoradiotherapy has been
shown to improve survival compared to PF, and it is sug-
gested as the preferred chemotherapy regimen when in-
duction treatment is used for management of HNSCCpatients. However, there is still little evidence from large
clinical trials that the use of induction TPF prior to
locoregional treatment improves survival when com-
pared to locoregional treatment alone. Furthermore, it is
unknown whether induction TPF improves outcomes
when given prior to surgery in patients with locally ad-
vanced and resectable HNSCC. Several clinical trials of
epidermal growth factor receptor inhibitors suggest the
targeted drugs could improve locoregional control and
survival in HNSCC patients with primary, recurrent or
distant metastatic lesions; cetuximab, for example, is
now firmly established as an active component of treat-
ment for advanced HNSCC, alone and in combination
with other modalities, including radiotherapy, platinum-
based chemotherapy and induction therapy. Cetuximab
has been approved by the Food and Drug Administration
(FDA) USA, for HNSCC treatment in combination with
radiotherapy for locally advanced, potentially curable dis-
ease, and as a single agent for incurable recurrent or
metastatic disease [30-33]. Additional clinical trials are
warranted to determine the benefit of adding an epider-
mal growth factor receptor (EGFR)-targeted agent in the
setting of locally advanced and resectable HNSCC.
As we know, the different response to induction
chemotherapy could lead to different survival, with good
response always leading to good survival, bad response
leading to poor survival [16]. Some predictive bio-
markers reflecting the response to induction chemother-
apy could be helpful for the next treatment choice, or in
deciding whether induction chemotherapy should be
performed, especially for resectable lesions. If the indi-
vidual biomarkers predict bad response to induction
chemotherapy, it should not be performed in those pa-
tients; otherwise, induction chemotherapy could benefit
both patient response and survival. The biomarkers in-
clude DNA sequence mutations, epigenetic changes, and
levels of messenger RNA or protein expression. For ex-
ample, in a prospective study [34], p53 gene mutations
are strongly associated with a poor risk of both objective
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apy, suggesting that patients with HNSCC should first
be screened for p53 mutations, before choosing the most
appropriate treatment protocol based on the mutations.
For organ preservation, it has been well-recognized that
in patients who respond to it, induction chemotherapy,
followed by radiotherapy or chemoradiotherapy, instead
of radical surgery, could benefit patients with laryngeal
cancer by preserving the larynx, without a negative im-
pact on overall survival and disease-free survival. For
other organs, although the response rate to induction
chemotherapy is relative high (50% to 80%) in the resect-
able lesions, which provides a better chance to eradicate
the locoregional lesions by radical surgery, there is no
conclusive evidence that induction chemotherapy confers
the benefit of organ preservation. A report by Licitra
et al. [16] revealed that induction chemotherapy can re-
duce the number of patients requiring mandibulectomy
and/or radiation therapy. However, there are no further
reports on the differences in survival or locoregional re-
currence between patients who do or do not undergo
mandibulectomy and/or radiotherapy. In our opinion, in
order to remove the tumor completely, emphasis should
placed on surgical resection being performed according
to the original tumor borders, which are marked with tat-
too or ink before treatment initiation, regardless of the re-
sponse to induction chemotherapy. In this study, there
was no evidence of significant differences in relation to
benefit for locoregional control between patients receiving
or not receiving induction chemotherapy. Further trials
are needed to resolve whether induction chemotherapy
can lead to organ perseveration of non-laryngeal sites.
Conclusions
In conclusion, there is a significant benefit of induction
chemotherapy in reducing distant metastases in patients
with locally advanced and resectable HNSCC; however,
there is no strong evidence of benefit in survival or
locoregional control. In contrast, induction chemother-
apy can be quite effective for preservation of the larynx.
Further research on non-laryngeal organ preservation
are encouraged using optimized induction chemotherapy
protocols, and also evaluating molecular biomarkers that
could help to identify those patients most likely, or un-
likely to benefit from the addition of induction chemo-
therapy to their treatment regimen.
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